Clinical Trial Update: Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating avelumab plus trabectedin in metastatic or unresectable liposarcoma and leiomyosarcoma; the study has terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Liposarcoma
• Unresectable Leiomyosarcoma
• Unresectable Liposarcoma

Drugs mentioned

• Avelumab (avelumab)
• Trabectedin (trabectedin)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Metastatic Leiomyosarcoma, Metastatic Liposarcoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-04-29